Protriptyline, sold under the brand name Vivactil among others, is a tricyclic antidepressant, specifically a secondary amine. Uniquely among most of the TCAs, protriptyline tends to be energizing instead of sedating, and is sometimes used for narcolepsy. At a pharmacologic level protriptyline preferentially inhibits norepinephrine reuptake with lesser activity at serotonin transporters, which accounts for a relative noradrenergic predominance and stimulant clinical profile; it also exhibits modest antagonism at H1 histamine, alpha-1 adrenergic, and muscarinic receptors that contributes to side effect liability but is generally less anticholinergic than many tertiary-amine TCAs. The drug is well absorbed orally, undergoes hepatic biotransformation including N-demethylation to the active metabolite norprotriptyline, and is eliminated primarily by renal excretion of metabolites; plasma protein binding and metabolic clearance can affect steady state and interactions with cytochrome P450 substrates should be considered in clinical use.
Parent: Protriptyline
Commercial active pharmaceutical ingredient specifications routinely monitor and control a profile of related compounds, oxidative products, and residual solvents rather than a single universal contaminant; typical identified related substances include norprotriptyline (desmethyl impurity), protriptyline N-oxide, positional isomers of the dibenzocycloheptene core, and occasional oxidative or dehydration byproducts. Common quality control acceptance criteria for the API are individual identified related compounds not more than 0.2 percent w/w, total related compounds not more than 1.0 percent w/w, a specific control limit for norprotriptyline often set at or below 0.05 to 0.10 percent w/w depending on regulatory filing, N-oxide kept below about 0.1 percent w/w, residual solvents controlled to ICH Q3C limits, and heavy metals below typical pharmacopeial thresholds (for example less than 20 ppm) as verified by validated chromatographic and spectroscopic assays.
Protriptyline is used primarily for depressive disorders and, because of its activating effects, has been used in the management of excessive daytime sleepiness and narcolepsy in selected patients under specialist supervision.
Amitriptyline is a tertiary-amine tricyclic antidepressant with relatively greater anticholinergic and sedative effects and stronger serotonin reuptake inhibition, while protriptyline is a secondary-amine TCA with greater noradrenergic selectivity, a more activating clinical profile, and generally less pronounced antimuscarinic activity.
Protriptyline is not a first line treatment for ADHD; stimulant medications and specific nonstimulant ADHD agents are the standard of care. Protriptyline has occasionally been tried off-label for attention and wakefulness issues because of its noradrenergic effects but evidence and guidance are limited and specialist oversight is required.
Weight changes can occur with tricyclic antidepressants. Protriptyline can cause weight gain in some patients, though its relatively activating noradrenergic profile may produce less pronounced weight gain than more sedating TCAs in some individuals.
